Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

BACKGROUND: Arginine-depleting therapy with pegylated arginine deiminase (ADI-PEG20) was reported to have activity in advanced melanoma in early phase I–II trial, and clinical trials are currently underway in other cancers. However, the optimal patient population who benefit from this treatment is u...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Feun, L G, Marini, A, Walker, G, Elgart, G, Moffat, F, Rodgers, S E, Wu, C J, You, M, Wangpaichitr, M, Kuo, M T, Sisson, W, Jungbluth, A A, Bomalaski, J, Savaraj, N
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2012
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3341859/
https://ncbi.nlm.nih.gov/pubmed/22472884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.106
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak